Progabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. In... In clinical trials, progabide has been investigated for Parkinson's disease, schizophrenia, clinical depression and anxiety disorder; its therapeutic effectiveness in these conditions is not fully elucidated.
- Mechanism
- Curator reviewed
Progabide binds to both GABAA and GABAB receptors located on the terminals of primary afferent fibers. Binding to GABAA results in an increased affinity of the GABA receptor for the amino acid, an augmented flux of chloride ions across the terminal membrane, and an increase in the amount of presynaptic inhibition. Activation of the GABAB receptors retards the influx of calcium ions into the terminals, thereby reducing the evoked release of excitatory amino acids and possibly other transmitters.
- Primary indication
- Indicated for the treatment of epilepsy.Curator reviewed
- Formula / weight
- C17H16ClFN2O2 · 334.78 g/mol (avg)
- Also known as
- Halogabide
- Code names
- SL-76002
Resolves to
IBALRBWGSVJPAP-UHFFFAOYSA-NSMILESOC(=N)CCCN=C(C1=CC=C(Cl)C=C1)C1=C(O)C=CC(F)=C1What you can answer from here — as of September 13, 2026
Which drugs share a target with Progabide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account